. .

-

. . *, ,
. . *,
. . *
. . *
. . **, ,
* . . . ,
** . . . ,

() -. 25% 50% . , 1523% , , 2/3 , , . , 3040 [1, 2]. - , , , , [35].

, , . , , , , [6, 7].

. [8]. (, , ), [9, 10]. , [11].

, , [12]. , . , , -1- -2, [13].

() [14, 15]. , [16]. , 336% , , [17]. , , , , , - [18]. [19]. toll- [20].

, - () . , , , , . , [21].

, , . , 75% . 29% [22, 23].

. , , , . - : S-100 (- S100), (- ) - (-α) (- ). - S100 S100, , , , , . - S100 , , , . - - , , . - -α . - ( ) -α, (-1, -6, -4, -10), -. , - . [24].

.

53 (39 14 ).

: , .

50 , , , , , , , , , , .

: 1- 32 (8 24 ) (-); 2- 21 (6 , 15 ) (-). 37,2 1,3 . 2 2 12 . (, ). , 1- 5 - 3 -.

III (2006 .) [22]. - ; ( , , ).

: - () (Visual Analog Scale Irritable Bowel Syndrome VAS-IBS), (Visceral Sensitivity Index VSI), (Irritable Bowel Syndrome Quality of Life IBS-QoL), .

. ( 91500.11.00042003, 231 09.06.2003). . 4 . KDL.

5 12 . . Excel Statistica 6.0 , . , .

5.

- - 24,3 0,34 21,4 0,64 .

. 74,5% .

- 10- 0,6 0,3 (. 1). 12 - 0,4 .

- : 5,3 0,18 . 0,2 (p < 0,05).

(Visceral Sensitivity Index VSI) . 2. -, 23,4 78,8 (p < 0,05). - , . - (r = 0,57; < 0,05). , .

. [22], . - 37 , . 6- 7- . 35 , 2 ( 1,1) (. 3).

- 35 ( 4,3 ). 1 1 2 ( 1 ). : 67 4- .

() Irritable Bowel Syndrome Quality of Life (IBS-QoL). . 24,6 66,6. , - , .

, , . - , . - -.

12- : , , , . (r₁ = 0,4 p < 0,05), (r₂ = 0,3 p < 0,05) .

(. 4).

, , , ; , , .

, . ( , ) ( ) . , , [25]. , . . . 84,5% . - 1- 40,6% , 2- 46,9%. - 1- 57,1%, 2- 33,4%. 12,5% 9,5% (. 5).

( ) (E. coli, Enterococcus spp., Streptococcus spp., Proteus spp., Candida).

, 1- 2- (. 6).

, 4 12 , . . , - , 128 , , [26].

, - -α . - S100, - - , , , , . , , , .

1. 12 : , , .
2. , , , , .
3. 4 12- . 12,5% 47% - 9,5% 62% - . .
4. , .

1. . ., . ., . . // - . 2012; 2: 232237.
2. . ., . . : // . 2015; 6: 410.
3. Canavan C., West J., Card T. Review article: the economic impact of the irritable bowel syndrome // Aliment. Pharmacol. Ther. 2014; 40: 10231034.
4. Koloski N., Boyce P., Jones M., Talley N. What level of IBS symptoms drives impairment in health-related quality of life in community subjects with irritable bowel syndrome? // Qual Life Res. 2012; 21: 829836.
5. Monnikes H. Quality of life in patients with irritable bowel syndrome // J. Clin. Gastroenterol. 2011; 45 (Suppl.): 98101.
6. Bindels L. B., Dewulf E. M., Delzenne N. M. GPR43/FFA2: physiopathological relevance and therapeutic prospects // Trends Pharmacol Sci. 2013; 34: 226232.
7. Muscatello M. R., Bruno A., Scimeca G., Pandolfo G., Zoccali R. A. Role of negative affects in pathophysiology and clinical expression of irritable bowel syndrome // World J. Gastroenterol. 2014; 20: 75707586.
8. Berman S., Suyenobu B., Naliboff B. D. et al. Evidence for alterations in central noradrenergic signaling in irritable bowel syndrome // Neuroimage. 2012; 63: 18541863.
9. Ohman L., Stridsberg M., Isaksson S., Jerlstad P., Simren M. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? // Am. J. Gastroenterol. 2012; 107: 440447.
10. . ., . ., . . - // . 2015; 3: 813.
11. Macsharry J., OMahony L., Fanning A., Bairead E., Sherlock G., Tiesman J., Fulmer A., Kiely B., Dinan T. G., Shanahan F. et al. Mucosal cytokine imbalance in irritable bowel syndrome // Scand J Gastroenterol. 2008; 43: 14671476.
12. Barbara G., Wang B., Stranghellini V. et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome // Gastroenterol. 2007; 132: 2637.
13. Guilarte M., Santos J., de Torres I., Alonso C., Vicario M.., Ramos L. et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum // Gut. 2007; 56: 203209.
14. Simren M., Barbara G., Flint H. J., Spiegel B. M., Spiller R. C., Vanner S. et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report // Gut. 2013; 62: 159166.
15. Natividad J. M., Verdu E. F. Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications // Pharmacol Res. 2013; 69: 4251.
16. Mearin F., Perez-Oliveras M., Perello A., Vinyet J., Ibanez A., Coderch J. et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study // Gastroenterology. 2005; 129: 98104.
17. Thabane M., Kottachchi D. T., Marshall J. K. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome // Aliment Pharmacol Ther. 2007; 26: 535544.
18. Natividad J. M., Verdu E. F. Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications // Pharmacol Res. 2013; 69: 4251.
19. Tana C., Umesaki Y., Imaoka A., Handa T., Kanazawa M., Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome // Neurogastroenterol Motil. 2010; 22: 512519.
20. Brint E. K., MacSharry J., Fanning A., Shanahan F., Quigley E. M. Differential expression of toll-like receptors in patients with irritable bowel syndrome // Am J Gastroenterol. 2011; 106: 329336.
21. Hyland N. P., Quigley E. M., Brint E. Microbiota host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions // World journal of gastroenterology: WJG. 2014; 20 (27): 88598866.
22. Drossman D. A., Dumitrascu D. L. Rome III: New standard for functional gastrointestinal disorders // J. Gastrointestin. Liver Dis. 2006; 15: 237241.
23. Quigley E. M., Abdel-Hamid H., Barbara G., Bhatia S. J., Boeckxstaens G., de Giorgio R., Delvaux M., Drossman D. A., Foxx-Orenstein A. E., Guarner F. et al. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome // J Clin Gastroenterol. 2012; 46: 356366.
24. . . // . 2015; 1: 5759.
25. . ., . . , // Consilium Medicum. 2000, 2 (7). http://www.con-med.ru/magazines/consilium_medicum/consilium_medicum-072000/.
26. . ., . ., . ., . ., . ., . . . : - // onsilium Medicum (). 2014; 1: 3643.